Drugs / AP301
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06100627 | Jan → Feb 2024 | — | Alebund Pty Ltd | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03567577 | May 2018 → Dec 2024 | acute respiratory distress syndrome | Apeptico Forschung und Entwicklung GmbH | Completed | No outcome recorded |
| Phase 2 | NCT02095626 | Jun 2013 → Mar 2015 | — | Apeptico Forschung und Entwicklung GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01627613 | Jul 2012 → May 2014 | acute lung injury | Apeptico Forschung und Entwicklung GmbH | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06933472 | Jun 2025 → Jun 2026 overdue | end stage renal failure, hyperphosphatemia | Alebund Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07030595 | Jun 2023 → Oct 2024 | end stage renal failure, hyperphosphatemia | Alebund Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP301 | “orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days” NCT02095626 ↗ |
| Known as | Solnatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03567577 ↗ |
| Action | Activate | “AP301 enhances AFC by activating epithelial sodium channels (ENaCs) on alveolar epithelial cells” PMID 28750677 ↗ Jul 2017 |
| Route | Inhaled | “Patients were treated with inhaled AP301 (n = 20) or placebo (0.9% NaCl; n = 20) twice daily for 7 days.” PMID 28750677 ↗ Jul 2017 |